Tirzepatide is a synthetic dual incretin receptor agonist that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Its unique dual-agonist profile makes it a highly valuable compound for researchers studying multi-pathway metabolic signalling, receptor pharmacology, and gut-brain axis modulation. Available in 10mg, 20mg, 30mg and 40mg vials. Every batch is HPLC tested and independently verified to a minimum of 99% purity. Certificate of Analysis available on request.